## Supplementary material

Wita M, Orszulak M, Szydło K, et al. The usefulness of telemedicine devices in patients with severe heart failure with an implanted cardiac resynchronization therapy system during two years of observation. Kardiol Pol. 2022.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Pharmacotherapy	Study group	Control group	<i>P</i> -value
Loop diuretic, %	89	90	0.86
β-blocker, %	85.7	100	0.03
Angiotensin-converting enzyme inhibitor, %	78.6	65.6	0.27
Angiotensin II receptor antagonist, %	7.1	3.1	0.48
Mineralocorticoid receptor antagonist, %	96.4	81.2	0.07

## Table S1. Pharmacotherapy in groups